Astellas Pharma Stock Sees Short Interest Increase Amid Analyst Downgrade
1 report, 1 independent
Updated Mon 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Astellas Pharma, a Japan-based pharmaceutical company, saw its short interest increase by 519.9% between September 15th and September 30th, totaling 155,427 shares. The company's stock opened at $14.35, maintaining a market capitalization of $25.97 billion. Zacks Research downgraded the company from a “strong-buy” rating to a “hold” rating on July 22nd.
From dailypolitical.com
Why it matters
The increased short interest and the downgrade from Zacks Research reflect market sentiment regarding Astellas Pharma's valuation and performance. The company researches, develops, manufactures, and commercializes prescription medicines, with a portfolio centered on areas like oncology and immunology.
From dailypolitical.com
Who's involved
- Astellas PharmaJapan-based pharmaceutical company that researches and commercializes prescription medicines